Page last updated: 2024-12-08

tempace

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tempace: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID518988
CHEBI ID180673
MeSH IDM0272976

Synonyms (28)

Synonym
CHEBI:180673
4-acetamido-2,2,6,6-tetramethylpiperidine-1-oxyl
2,2,6,6-tetramethyl-4-acetamidopiperidine-1-oxyl
4-acetamido-2,2,6,6-tetramethylpiperidinyloxyl
4-acetamido-tempo, free radical, 97%
tempace
4-acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl
FT-0653861
unii-g7abj73l6s
(4-acetamido-2,2,6,6-tetramethyl-1-piperidinyl)oxidanyl
ec 423-840-3
g7abj73l6s ,
AKOS015910523
4-acetamido-tempo, free radical
W-201301
4-acetylamino-tempo
2,2,6,6-tetramethyl-4-acetamidopiperidin-1-oxyl
4-acetamide-2,2,6,6-tetramethyl-1-piperidin-yloxy
4-n-acetylamino-tempo
piperidinooxy, 4-acetamido-2,2,6,6-tetramethyl-
4-acetamino-2,2,6,6-tetramethylpiperidine-1-oxyl
mfcd00043593
4-acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl, purum, >=98.0% (hplc)
CS-0188148
4-acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl free radical [catalyst for oxidation]
DTXSID60932959
AS-17419
4-acetamido-2,2,6,6-tetramethylpiperidine1-oxyl

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The results clearly confirmed that the toxic effect could result either from the presence or structure of substituent(s) at position 4 of the free radical piperidine moiety."( Tempicol-3, a novel piperidine-N-oxide stable radical and antioxidant, with low toxicity acts as apoptosis inducer and cell proliferation modifier of Yoshida Sarcoma cells in vivo.
Gwoździnski, K; Głebska, J; Jóźwiak, Z; Koceva-Chyła, A; Kochman, A; Metodiewa, D,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
radical scavengerA role played by a substance that can react readily with, and thereby eliminate, radicals.
radiation protective agentAny compound that is able to protect normal cells from the damage caused by radiation therapy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
aminoxylsRadicals derived from hydroxylamines by removal of the hydrogen atom from the hydroxy group. The synonymous terms nitroxyl radicals and nitroxides erroneously suggest the presence of a nitro group.
piperidinecarboxamide
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (3)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.10 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]